Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. 2011

Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
Department of Clinical Laboratory Technology, Dalian Municipal Central Hospital, Dalian, Liaoning 116033, China. weihongliu1120@hotmail.com

Cancer sera contain antibodies that react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs), and therefore these autoantibodies can be considered as reporters from the immune system, to identify authentic TAAs involved in the malignant transformation. Once a TAA is identified, different approaches would be used to comprehensively characterize and validate the identified TAA/anti-TAA systems that are potential biomarkers in cancer immunodiagnosis. In this manner, several novel TAAs such as p62 and p90 have been identified in our previous studies. p62, a member of IGF-II mRNA binding proteins (IMPs), is an oncofetal protein absent in adult tissues, the presence of anti-p62 autoantibodies relates to abnormal expression of p62 in tumor cells. p90 was recently characterized as an inhibitor of the tumor suppressor PP2A (protein phosphatase 2A), and an autoantibody to p90 appears in high frequency in prostate cancer. The present review will focus on the recent advances in studies mainly associated with these two novel TAAs as biomarkers in cancer immunodiagnosis.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D001324 Autoantigens Endogenous tissue constituents with the ability to interact with AUTOANTIBODIES and cause an immune response. Autoantigen,Autologous Antigen,Autologous Antigens,Self-Antigen,Self-Antigens,Antigen, Autologous,Antigens, Autologous,Self Antigen,Self Antigens
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016601 RNA-Binding Proteins Proteins that bind to RNA molecules. Included here are RIBONUCLEOPROTEINS and other proteins whose function is to bind specifically to RNA. Double-Stranded RNA-Binding Protein,Double-Stranded RNA-Binding Proteins,ds RNA-Binding Protein,RNA-Binding Protein,ds RNA-Binding Proteins,Double Stranded RNA Binding Protein,Double Stranded RNA Binding Proteins,Protein, Double-Stranded RNA-Binding,Protein, ds RNA-Binding,RNA Binding Protein,RNA Binding Proteins,RNA-Binding Protein, Double-Stranded,RNA-Binding Protein, ds,RNA-Binding Proteins, Double-Stranded,ds RNA Binding Protein
D054648 Protein Phosphatase 2 A phosphoprotein phosphatase subtype that is comprised of a catalytic subunit and two different regulatory subunits. At least two genes encode isoforms of the protein phosphatase catalytic subunit, while several isoforms of regulatory subunits exist due to the presence of multiple genes and the alternative splicing of their mRNAs. Protein phosphatase 2 acts on a broad variety of cellular proteins and may play a role as a regulator of intracellular signaling processes. PPP2CA Phosphatase,PPP2CB Phosphatase,Protein Phosphatase 2, Catalytic Subunit,Protein Phosphatase 2, Catalytic Subunit, alpha Isoform,Protein Phosphatase 2, Catalytic Subunit, beta Isoform,Protein Phosphatase 2, Regulatory Subunit,Protein Phosphatase 2, Regulatory Subunit A, alpha Isoform,Protein Phosphatase 2, Regulatory Subunit A, beta Isoform,Protein Phosphatase 2, Regulatory Subunit B, alpha Isoform,Protein Phosphatase 2, Regulatory Subunit B, beta Isoform,Protein Phosphatase 2, Regulatory Subunit B, delta Isoform,Protein Phosphatase 2, Regulatory Subunit B, gamma Isoform,Protein Phosphatase 2A, Catalytic Subunit, alpha Isoform,Protein Phosphatase 2A, Catalytic Subunit, beta Isoform,Protein Phosphatase 2A, Regulatory Subunit A , alpha Isoform,Protein Phosphatase 2A, Regulatory Subunit A, beta Isoform,Protein Phosphatase 2A, Regulatory Subunit B, alpha Isoform,Protein Phosphatase 2A, Regulatory Subunit B, beta Isoform,Protein Phosphatase 2A, Regulatory Subunit B, delta Isoform,Protein Phosphatase 2A, Regulatory Subunit B, gamma Isoform,Protein Phosphatase-2A,Serine Threonine Protein Phosphatase 2A Catalytic Subunit beta Isoform,Serine-Threonine-Protein Phosphatase 2A Catalytic Subunit alpha Isoform,Phosphatase, PPP2CA,Phosphatase, PPP2CB,Protein Phosphatase 2A,Serine Threonine Protein Phosphatase 2A Catalytic Subunit alpha Isoform

Related Publications

Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
March 2010, Current molecular medicine,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
October 2013, Autoimmunity reviews,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
January 2008, Molecular medicine reports,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
February 2021, Translational oncology,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
February 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
April 2015, Journal of proteomics,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
May 2013, Experimental hematology & oncology,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
October 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
May 2014, Cancer letters,
Weihong Liu, and Bo Peng, and Yumin Lu, and Weijia Xu, and Wei Qian, and Jian-Ying Zhang
March 2012, Scandinavian journal of immunology,
Copied contents to your clipboard!